Core Viewpoint - Inner Mongolia has launched a comprehensive "Clearing Source" action to regulate drug distribution and enhance drug quality supervision, aiming to combat illegal activities in the pharmaceutical sector and ensure public safety in medication [1][2]. Group 1: Regulatory Actions - The Baotou Market Supervision Bureau has initiated the "Clearing Source" action from April to November, targeting illegal activities such as renting out licenses, manufacturing and selling counterfeit drugs, and selling prescription drugs without prescriptions [1]. - The Tongliao Market Supervision Bureau has implemented a "cloud supervision" system using facial recognition and GPS to monitor the on-duty status of licensed pharmacists in pharmacies, with 690 pharmacists already registered on the platform [1]. - The Xilin Gol League Market Supervision Bureau is focusing on retail drug enterprises and medical beauty clinics, inspecting for the sale of unapproved drugs and illegal procurement channels, having checked 123 retail drug enterprises and 13 other medical institutions [1]. Group 2: Focus Areas and Measures - The Ordos Market Supervision Bureau is conducting inspections on special drugs, centrally procured drugs, and Mongolian medicine formulations, particularly at major medical institutions [1]. - The Ulaanbaatar Market Supervision Bureau is focusing on potential risks in the drug distribution sector, including abnormal price fluctuations and procurement channels, while ensuring prescription drugs are sold strictly with prescriptions [2]. - The Alxa League regulatory departments are emphasizing inspections in rural areas and focusing on high-value drugs and special compound preparations, enhancing quality management in retail chain stores [2].

Core Viewpoint - The Guangzhou Market Supervision Administration has launched a "Clearing Source" action to regulate drug business practices and enhance drug quality supervision across the city [1] Group 1: Action Focus - The action targets issues such as the rental and lending of licenses, production and sale of counterfeit drugs, illegal drug purchases, and the sale of prescription drugs without prescriptions [1] - A leadership team has been established to oversee the "Clearing Source" action, with the Drug and Chemical Department leading the development of the action plan [1] Group 2: Responsibilities and Compliance - The action aims to reinforce the primary responsibility of drug operating enterprises and users, urging them to conduct self-inspections across all drug procurement, sales, storage, and usage stages [1] - Special attention will be given to wholesale enterprises, retail chain headquarters, and retail enterprises that engage in abnormally low-priced drug procurement [1] Group 3: Risk Management and Enforcement - The initiative will strengthen the approval and entry mechanisms, optimize the exit mechanisms, and enhance the management of retail chain enterprises [1] - Comprehensive checks will be conducted on enterprises with a history of complaints, multiple referrals, and inadequate rectifications, including online and offline inspections [1] - The action will involve collaboration with public security, health, and medical insurance departments to thoroughly investigate potential illegal activities and enforce strict penalties for violations [1]